Sildenafil: Study of a novel oral treatment for erectile dysfunction in diabetic men

Diabetic Medicine

Volumn 15, Issue 10, 1998, Pages 821-825

  Price, D E ^a   Gingell, J C ^b   Gepi Attee, S ^b   Wareham, K ^a   Yates, P ^c   Boolell, M ^c  

^a MORRISTON HOSPITAL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Diabetes; Erectile dysfunction; Phosphodiesterase inhibitors; Sildenafil

Indexed keywords

PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; HEADACHE; HUMAN; IMPOTENCE; MALE; MULTICENTER STUDY; MYALGIA; ORAL DRUG ADMINISTRATION; PENIS ERECTION; PLETHYSMOGRAPHY; RANDOMIZED CONTROLLED TRIAL;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADOLESCENT; ADULT; AGED; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FOLLOW-UP STUDIES; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PIPERAZINES; TREATMENT OUTCOME;

EID: 0031684711     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199810)15:10<821::AID-DIA697>3.0.CO;2-P     Document Type: Article

References (18)

1. Price DE, O'Malley BP, Roshan M, James M, Hearnshaw JR. Why are impotent diabetic men not being treated? Practical Diabetes 1991; 8: 10-11.
2. Smith AD. Causes and classification of impotence. Urol Clin North Am 1981; 8: 79-89.
3. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia 1980; 18: 279-283.
4. Benet AE, Sharaby JS, Melman A. Male erectile dysfunction assessment and treatment options. Compr Ther 1994; 20: 669-673.
5. Price DE, Cooksey G, Jehu D, Bentley S, Hearnshaw JR, Osborn DE. The management of impotence in diabetic men by vacuum tumescence therapy. Diabetic Med 1991; 8: 964-967.
6. Linet OI, Ogrinc F. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334: 873-877.
7. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997; 336: 1-7.
8. Price DE. Managing impotence in diabetes. Br Med J 1993; 307: 295-296.
9. Burnett AL. Nitric oxide in the penis: physiology and pathology. J Urol 1997; 157: 320-324.
10. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
11. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257-261.
12. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-1404.
13. Ogrinc FG, Linet OI. Evaluation of real-time RigiScan monitoring in pharmacological erection. J Urol 1995; 154: 1356-1359.
14. Jones B, Kenward MG. Design and Analysis of Crossover Trials. London: Chapman and Hall, 1989.
15. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320: 1025-1030.
16. Hoffman D, Seftel AD, Hampel N, Resnick MI. Advanced glycation end-products quench cavernosal nitric oxide (Abstract). J Urol 1995; 153: 441A.
17. Montague DK, Barada JH, Belker AM, Levine LA, Nadig PW, Roehrborn CG, et al. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol 1996; 156: 2007-2011.
18. Gomaa A, Shalaby M, Osman M, Eissa M, Eizat A, Mahmoud M, et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate. Br Med J 1996; 312: 1512-1515.